Pharmaceutically Produced Cannabidiol
Our pharmaceutically produced ultra-pure cannabidiol formulation has been developed specifically for medical purposes. It is free from the psychotropic effects of THC and is produced using controlled processes in approved current Good Manufacturing Practices (cGMP) pharmaceutical facilities. This allows for consistent quality, purity, and stability from batch to batch, resulting in a THC-free (<10 ppm) cannabidiol oil – ideal for patients who should not take THC.
CardiolRx is a cannabidiol formulation being developed for the treatment of inflammatory cardiovascular conditions. Cardiol’s initial clinical focus is on acute myocarditis – the leading cause of sudden cardiac death in people under 35 years of age.
Cardiol is currently conducting a Phase I safety and pharmacokinetic study of CardiolRx and is planning a Phase II study to investigate the therapeutic effects of CardiolRx on myocardial recovery in patients with acute myocarditis.
Cardiol is also developing a subcutaneous formulation of cannabidiol for the treatment of chronic heart failure. Heart failure affects over six million people in North America and remains a leading cause of death and hospitalization with associated U.S. healthcare costs exceeding $30 billion annually.
Cannabidiol is not known to have any psychoactive side effects, while THC can cause memory loss, slowed response times, and issues with coordination resulting in an impaired ability to drive. Young people under the age of 25 may also experience negative psychiatric and cognitive effects from THC as it may impair brain development. Elderly patients frequently have various conditions that impact coordination or cognition, both of which may lead to accidents when the individual has consumed THC.
If you would like to learn more about Cortalex, our pharmaceutically produced cannabidiol, please visit cortalex.com.